Home
NewsNewsFertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
FertilAI announced on April 15, 2026, that it has received CE marking under the EU Medical Device Regulation (EU MDR) for its clinical decision-support tools. The clearance applies to StimAI and OvuPredict, which are integrated into the company’s Fertilane platform to assist physicians with clinical timing during active treatment cycles. This development introduces a regulated application of Predictive AI in Fertility specifically designed to predict mature oocyte yields and natural cycle ovulation. StimAI, an EU MDR Class IIa device, forecasts the number of mature oocytes retrieved across different trigger timings to support IVF outcomes and laboratory workload management. OvuPredict, classified as EU MDR Class I, predicts ovulation up to six days in advance to assist in timing intrauterine insemination (IUI) and frozen embryo transfers (FET).
The Fertilane system is a SaaS solution that integrates with existing electronic medical record (EMR) systems. Its algorithms were developed using data from more than 100,000 cycles to support individualized care and operational scheduling. By utilizing Predictive AI in Fertility, the platform aims to reduce patient monitoring requirements and balance daily clinic workloads without affecting clinical outcomes. The technology is intended to provide data-driven insights during active treatment cycles, allowing for more predictable daily scheduling in both medical and laboratory environments.
Fertilane delivers two fertility-tailored algorithms:
FertilAI CEO Rohi Hourvitz stated that the EU MDR validation confirms the technology’s role in streamlining clinic operations and increasing service access without raising overhead. The advancement of Predictive AI in Fertility is positioned to address physician shortages and rising infertility rates. Hourvitz commented, "Our goal is to accelerate and ease the patients' fertility treatment journey to parenthood, no matter the path taken". He added, "With the global rise in infertility and a worldwide shortage of physicians driving higher costs and longer wait times, expanding access to care is absolutely vital. Having a system that enables clinic scalability while actively improving clinical benefits and the patient experience is a pivotal step forward in addressing this growing challenge".
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
INVO Fertility, Inc has confirmed that its Wisconsin Fertility Institute-WFI clinic joined the Progyny network, making advanced reproductive care more widely available and accessible for more patients seeking fertility treatment.
Births resulting from essential Infertility Treatments, including advanced procedures like artificial insemination and IVF, have seen a very positive and promising climb, accounting for almost 15.1% of the total births recorded in 2024.
The Fertility Society of Ghana has urged the government to officially recognize infertility as a disease and include basic fertility services in the National Health Insurance Scheme during its eighth Annual General meeting, held in Tema.
